{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:14:47Z","timestamp":1793650487281,"version":"4.5.1"},"reference-count":277,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1136\/ard-2023-223850","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T13:20:17Z","timestamp":1699017617000},"page":"139-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":169,"title":["Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct00550043","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03502616","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03288324","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03159936","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05016297","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03026504","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03579749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02535689","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03978520","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03345836","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03978520","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03725202","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04161898","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02914561","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03766399","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04769869","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04640168","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04421027","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04469114","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03915964","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03926195","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03201445","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-7482","authenticated-orcid":false,"given":"Michael","family":"Bonelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8873","authenticated-orcid":false,"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1393-3390","authenticated-orcid":false,"given":"Kastriot","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gadina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-1493","authenticated-orcid":false,"given":"Leonhard X","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-223850_bib1","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK\u2013STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard-2023-223850_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nri702","article-title":"Cytokines and Autoimmunity","volume":"2","author":"O'Shea","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard-2023-223850_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"And Stats: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ard-2023-223850_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"Jaks and Stats in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib5","first-page":"2415","article-title":"Jak3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells","volume":"9","author":"Rane","year":"1994","journal-title":"Oncogene"},{"key":"10.1136\/ard-2023-223850_bib6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.str.2016.05.007","article-title":"Jak1 takes a FERM hold of type II cytokine receptors","volume":"24","author":"Babon","year":"2016","journal-title":"Structure"},{"key":"10.1136\/ard-2023-223850_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"key":"10.1136\/ard-2023-223850_bib8","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"10.1136\/ard-2023-223850_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of JAK\u2013STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2023-223850_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1136\/ard-2023-223850_bib11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/emboj\/21.7.1754","article-title":"Regulated nuclear import of the Stat1 transcription factor by direct binding of Importin-alpha","volume":"21","author":"McBride","year":"2002","journal-title":"EMBO J"},{"key":"10.1136\/ard-2023-223850_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1359-6101(98)00012-4","article-title":"Nuclear import and export of proteins: the molecular basis for intracellular signaling","volume":"9","author":"Sekimoto","year":"1998","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1136\/ard-2023-223850_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention*","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1136\/ard-2023-223850_bib14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cell.2012.09.044","article-title":"Stats shape the active enhancer landscape of T cell populations","volume":"151","author":"Vahedi","year":"2012","journal-title":"Cell"},{"key":"10.1136\/ard-2023-223850_bib15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","article-title":"The \u0393c family of Cytokines: basic biology to therapeutic ramifications","volume":"50","author":"Leonard","year":"2019","journal-title":"Immunity"},{"key":"10.1136\/ard-2023-223850_bib16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by \u0393c family Cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard-2023-223850_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/370151a0","article-title":"Phosphorylation and activation of the Jak-3 Janus kinase in response to Interleukin-2","volume":"370","author":"Johnston","year":"1994","journal-title":"Nature"},{"key":"10.1136\/ard-2023-223850_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN\u03b1 signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"issue":"Pt 2","key":"10.1136\/ard-2023-223850_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj3340297","article-title":"M\u00fcLLER-NEWEN G, et Al. Interleukin-6-type cytokine signalling through the Gp130\/JAK\/STAT pathway","volume":"334","author":"Heinrich","year":"1998","journal-title":"Biochem J"},{"key":"10.1136\/ard-2023-223850_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4049\/jimmunol.153.1.128","article-title":"Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor Superfamily with strong Homology to Gp130","volume":"153","author":"Chua","year":"1994","journal-title":"The Journal of Immunology"},{"key":"10.1136\/ard-2023-223850_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.181.1.399","article-title":"Interleukin 12 (IL-12) induces tyrosine Phosphorylation of Jak2 and Tyk2: differential use of Janus family tyrosine Kinases by IL-2 and IL-12","volume":"181","author":"Bacon","year":"1995","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2023-223850_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus Kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1136\/ard-2023-223850_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri1648","article-title":"New IL-12-family members: IL-23 and IL-27, Cytokines with divergent functions","volume":"5","author":"Hunter","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard-2023-223850_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1146\/annurev.bi.59.070190.004031","article-title":"Cytokines: Coordinators of immune and inflammatory responses","volume":"59","author":"Arai","year":"1990","journal-title":"Annu Rev Biochem"},{"key":"10.1136\/ard-2023-223850_bib25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0092-8674(00)81288-X","article-title":"Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK\u2013STAT signaling pathway","volume":"84","author":"Meraz","year":"1996","journal-title":"Cell"},{"key":"10.1136\/ard-2023-223850_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semcdb.2008.08.010","article-title":"Inteferons pen the JAK\u2013STAT pathway","volume":"19","author":"Schindler","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"10.1136\/ard-2023-223850_bib27","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from Interferons to Cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1136\/ard-2023-223850_bib28","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1126\/science.1281555","article-title":"Activation of transcription by IFN-gamma: tyrosine Phosphorylation of a 91-kD DNA binding protein","volume":"258","author":"Shuai","year":"1992","journal-title":"Science"},{"key":"10.1136\/ard-2023-223850_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1471-4906(01)02149-4","article-title":"The Interleukin-10 family of Cytokines","volume":"23","author":"Fickenscher","year":"2002","journal-title":"Trends Immunol"},{"key":"10.1136\/ard-2023-223850_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and Nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"key":"10.1136\/ard-2023-223850_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13992","article-title":"Biallelic Jak1 mutations in immunodeficient patient with Mycobacterial infection","volume":"7","author":"Eletto","year":"2016","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2023-223850_bib32","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.jaci.2016.12.957","article-title":"Jak1 gain-of-function causes an Autosomal dominant immune Dysregulatory and Hypereosinophilic syndrome","volume":"139","author":"Del Bel","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2023-223850_bib33","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/art.40216","article-title":"Genome\u2010Wide Association Meta\u2010Analysis reveals novel juvenile idiopathic arthritis susceptibility Loci","volume":"69","author":"McIntosh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083540","article-title":"Clinical significance of asthma clusters by longitudinal analysis in Korean asthma cohort","volume":"8","author":"Park","year":"2013","journal-title":"PLoS One"},{"key":"10.1136\/ard-2023-223850_bib35","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/stem.1711","article-title":"Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells","volume":"32","author":"Akada","year":"2014","journal-title":"Stem Cells"},{"key":"10.1136\/ard-2023-223850_bib36","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1167\/iovs.11-8440","article-title":"Jak2 and Stat3 Polymorphisms in a Han Chinese population with Behcet's disease","volume":"53","author":"Hu","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1136\/ard-2023-223850_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01824","article-title":"An activating Janus Kinase-3 Mutation is associated with cytotoxic T lymphocyte Antigen-4-dependent immune dysregulation syndrome","volume":"8","author":"Sic","year":"2017","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"10.1136\/ard-2023-223850_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-142078","article-title":"Germline gain-of-function Jak3 Mutation in familial chronic lymphoproliferative disorder of NK cells","volume":"136","author":"Lesmana","year":"2020","journal-title":"Blood"},{"key":"10.1136\/ard-2023-223850_bib39","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1007\/s11033-010-0601-5","article-title":"Meta-analysis of Tyk2 gene Polymorphisms association with susceptibility to autoimmune and inflammatory diseases","volume":"38","author":"Tao","year":"2011","journal-title":"Mol Biol Rep"},{"key":"10.1136\/ard-2023-223850_bib40","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4049\/jimmunol.1203118","article-title":"Two rare disease-associated Tyk2 variants are Catalytically impaired but signaling competent","volume":"190","author":"Li","year":"2013","journal-title":"J Immunol"},{"key":"10.1136\/ard-2023-223850_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122271","article-title":"Tyk2 protein-coding variants protect against rheumatoid arthritis and Autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits","volume":"10","author":"Diogo","year":"2015","journal-title":"PLoS One"},{"key":"10.1136\/ard-2023-223850_bib42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.humimm.2012.09.007","article-title":"Tyk2 Rs34536443 polymorphism is associated with a decreased susceptibility to Endometriosis-related infertility","volume":"74","author":"Peluso","year":"2013","journal-title":"Hum Immunol"},{"key":"10.1136\/ard-2023-223850_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau8714","article-title":"Tuberculosis and impaired IL-23\u2013dependent IFN-\u0393 immunity in humans homozygous for a common Tyk2 Missense variant","volume":"3","author":"Boisson-Dupuis","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1136\/ard-2023-223850_bib44","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human Tyk2 deficiency: Mycobacterial and viral infections without hyper-IGE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2023-223850_bib45","author":"Lv"},{"key":"10.1136\/ard-2023-223850_bib46","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.2147\/IDR.S279438","article-title":"Mycobacterium Intracellulare infection associated with Tyk2 deficiency: A case report and review of the literature","author":"Guo","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1136\/ard-2023-223850_bib47","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jaci.2012.11.054","article-title":"Dominant gain-of-function Stat1 mutations in Foxp3 wild-type immune dysregulation-Polyendocrinopathy-Enteropathy-X-linked-like syndrome","volume":"131","author":"Uzel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2023-223850_bib48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12185-020-02860-7","article-title":"Ruxolitinib treatment of a patient with steroid-dependent severe Autoimmunity due to Stat1 gain-of-function Mutation","volume":"112","author":"Moriya","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1136\/ard-2023-223850_bib49","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10875-018-0519-6","article-title":"Utility of Ruxolitinib in a child with chronic Mucocutaneous Candidiasis caused by a novel Stat1 gain-of-function Mutation","volume":"38","author":"Bloomfield","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1136\/ard-2023-223850_bib50","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJMc2022226","article-title":"Stat1 gain of function, type 1 diabetes, and reversal with JAK inhibition","volume":"383","author":"Chaimowitz","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1136\/ard-2023-223850_bib52","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192319","article-title":"Homozygous Stat2 gain-of-function Mutation by loss of Usp18 activity in a patient with type I Interferonopathy","volume":"217","author":"Gruber","year":"2020","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2023-223850_bib53","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic Stat3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib54","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide Association studies for Crohn disease and psoriasis identifies seven shared susceptibility Loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1136\/ard-2023-223850_bib55","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa073003","article-title":"Stat4And the risk of rheumatoid arthritis and systemic lupus erythematosus","volume":"357","author":"Remmers","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib56","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/infdis\/jix522","article-title":"Paracoccidioidomycosis associated with a heterozygous Stat4 Mutation and impaired IFN-\u0393 immunity","volume":"216","author":"Schimke","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1136\/ard-2023-223850_bib57","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/hmg\/11.6.613","article-title":"Stat6 as an asthma candidate gene: polymorphism-screening, Association and haplotype analysis in a Caucasian Sib-pair study","volume":"11","author":"Duetsch","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1136\/ard-2023-223850_bib58","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2022.12.802","article-title":"Stat6 gain-of-function variant exacerbates multiple allergic symptoms","volume":"151","author":"Takeuchi","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2023-223850_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18925-4","article-title":"Early-onset Autoimmunity associated with Socs1 Haploinsufficiency","volume":"11","author":"Hadjadj","year":"2020","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2023-223850_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11496","article-title":"Isg15 deficiency and increased viral resistance in humans but not mice","volume":"7","author":"Speer","year":"2016","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2023-223850_bib61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.it.2016.11.001","article-title":"Isg15: in sickness and in health","volume":"38","author":"Hermann","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1136\/ard-2023-223850_bib62","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1056\/NEJMoa1905633","article-title":"JAK inhibitor therapy in a child with inherited Usp18 deficiency","volume":"382","author":"Alsohime","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib63","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in Lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"10.1136\/ard-2023-223850_bib64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2012.23","article-title":"The pathogenesis of rheumatoid arthritis: new insights from old clinical data?","volume":"8","author":"Smolen","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","article-title":"Forget Personalised medicine and focus on abating disease activity","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib66","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with Etanercept and Anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-223850_bib67","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective Costimulation modulation using Abatacept in patients with active rheumatoid arthritis while receiving Etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib68","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3899\/jrheum.100602","article-title":"A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a P38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis","volume":"38","author":"Genovese","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib69","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3899\/jrheum.140238","article-title":"A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of Fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-\u0391 antagonist","volume":"41","author":"Genovese","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib70","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: A randomized, Double\u2010Blind, phase II trial","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21145164","article-title":"Small molecule NF-\u039aB pathway inhibitors in clinic","volume":"21","author":"Ramadass","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ard-2023-223850_bib72","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"10.1136\/ard-2023-223850_bib73","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function Mutation of Jak2 in Myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib74","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of Ruxolitinib across patient subgroups: analysis of a Placebo\u2010Controlled, phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1136\/ard-2023-223850_bib75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood-2018-99-116342","article-title":"Results from Reach1, a single-arm phase 2 study of Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease","volume":"132","author":"Jagasia","year":"2018","journal-title":"Blood"},{"key":"10.1136\/ard-2023-223850_bib76","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib77","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib78","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-223850_bib79","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib80","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.berh.2010.02.003","article-title":"Inhibition of JAK Kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes","volume":"24","author":"Riese","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib82","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and Adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3B\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib83","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus placebo for Psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib84","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for Psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib85","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with Ankylosing Spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib86","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of Ankylosing Spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib87","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2B randomized Placebo\u2010Controlled Dose\u2010Ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib88","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus Etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib89","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib90","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1136\/ard-2023-223850_bib91","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib92","first-page":"1485","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterology Hepatology Official Clin Pract J Am Gastroenterological Assoc"},{"key":"10.1136\/ard-2023-223850_bib93","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"key":"10.1136\/ard-2023-223850_bib94","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2023-223850_bib95","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/annrheumdis-2018-213836","article-title":"Interferon-\u0391 enhances the IL-12-induced Stat4 activation selectively in carriers of the Stat4 SLE risk allele Rs7574865[T]","volume":"78","author":"Hagberg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib96","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor Peficitinib (Asp015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib97","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying Antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib98","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib99","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of Peficitinib (Asp015K) in patients with rheumatoid arthritis and an inadequate response to conventional Dmards: a randomised, double-blind, placebo-controlled phase III trial (Raj3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib100","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of Peficitinib (Asp015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (Raj4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib101","article-title":"Ab0492 JAK-inhibition with Peficitinib and Filgotinib in fibroblast-like Synoviocytes in rheumatoid arthritis","author":"Diller","year":"2018","journal-title":"Annual European Congress of Rheumatology, EULAR 2018, Amsterdam"},{"key":"10.1136\/ard-2023-223850_bib102","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2A randomized, Double\u2010Blind, Placebo\u2010Controlled, sequential Dose\u2010Escalation study to evaluate the efficacy and safety of Asp015K, a novel Janus kinase inhibitor, in patients with Moderate\u2010To\u2010Severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib103","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral Janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study","volume":"12","author":"Sands","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1136\/ard-2023-223850_bib104","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of Baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib105","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior Disease\u2010Modifying Antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib106","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2016-209821","article-title":"Patient-reported outcomes from a randomised phase III study of Baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib107","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic Dmards: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib108","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-reported outcomes from a phase 3 study of Baricitinib versus placebo or Adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study","volume":"76","author":"Keystone","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib109","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/14397595.2017.1392057","article-title":"Efficacy and safety of Baricitinib in Japanese patients with rheumatoid arthritis: subgroup analyses of four multinational phase 3 randomized trials","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and safety of Baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: A 12-week, double-blind, randomized placebo-controlled study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib111","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib112","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s10067-018-4221-0","article-title":"Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, Baricitinib, or Baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study","volume":"37","author":"van der Heijde","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib113","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or Adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib114","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2B trial of Baricitinib, an oral Janus kinase (JAK) 1\/Jak2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with Moderate\u2010To\u2010Severe Atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib116","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe Atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-Ad5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib117","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of Baricitinib combined with topical corticosteroids for treatment of moderate to severe Atopic dermatitis: A randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1136\/ard-2023-223850_bib118","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib119","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib120","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib121","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of Baricitinib for Alopecia Areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic Armamentarium_ the small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1136\/ard-2023-223850_bib123","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: first approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"10.1136\/ard-2023-223850_bib124","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib126","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of Upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib127","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of Upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-223850_bib128","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT\u2010494, a selective JAK\u20101 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti\u2013tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib129","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of Upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib130","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of Upadacitinib in patients with active Ankylosing Spondylitis (SELECT-AXIS 1): a Multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib131","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.41911","article-title":"Safety and efficacy of Upadacitinib in patients with active Ankylosing Spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: One\u2010Year results of a Double\u2010Blind, Placebo\u2010Controlled study and Open\u2010Label extension","volume":"74","author":"Deodhar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib132","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or Adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib133","first-page":"275","article-title":"Efficacy and safety of Upadacitinib in patients with Psoriatic arthritis: 2-year results from the phase 3 SELECT-PSA 1 study","volume":"10","author":"McInnes","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2023-223850_bib134","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib135","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of Upadacitinib for active Ankylosing Spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib136","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of Upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1136\/ard-2023-223850_bib137","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, Multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib138","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of Upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1136\/ard-2023-223850_bib139","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe Atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2023-223850_bib140","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of Upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe Atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib141","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily Upadacitinib versus placebo in adolescents and adults with moderate-to-severe Atopic dermatitis (measure up 1 and measure up 2): results from two Replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib142","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of Filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying Antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1136\/ard-2023-223850_bib143","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib144","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib145","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/mr\/roab030","article-title":"Efficacy and safety of Filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib146","first-page":"71","article-title":"Efficacy and safety of Filgotinib in patients with high risk of poor prognosis who showed inadequate response to MTX: A post hoc analysis of the FINCH 1 study","volume":"10","author":"Combe","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2023-223850_bib147","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of Filgotinib, a selective Janus kinase 1 inhibitor, in patients with active Psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib148","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of Filgotinib, a selective Janus kinase 1 inhibitor, in patients with active Ankylosing Spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib149","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with Filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib150","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2B\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib151","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.gastro.2023.03.234","article-title":"Filgotinib for the treatment of small bowel Crohn's disease: the DIVERGENCE 1 trial","volume":"165","author":"D'Haens","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1136\/ard-2023-223850_bib152","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of Abrocitinib in adults and adolescents with moderate-to-severe Atopic dermatitis (JADE MONO-1): a Multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib153","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of Abrocitinib in patients with moderate-to-severe Atopic dermatitis: A randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1136\/ard-2023-223850_bib154","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or Dupilumab for Atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, Double\u2010Blind, Placebo\u2010Controlled, Twelve\u2010Week, Dose\u2010Ranging study of Decernotinib, an oral selective JAK\u20103 inhibitor, as monotherapy in patients with active rheumatoid arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib156","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib157","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1136\/annrheumdis-2015-208901","article-title":"Efficacy of VX-509 (Decernotinib) in combination with a disease-modifying Antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings","volume":"75","author":"Genovese","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib158","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and safety of PF\u201006651600 (Ritlecitinib), a novel Jak3\/TEC inhibitor, in patients with Moderate\u2010To\u2010Severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib159","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2A randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 And Janus Kinase-Signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib161","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and Apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib162","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and Apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program fOr evaluation of Tyk2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib163","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective Tyk2 inhibitor, Deucravacitinib, in a phase II trial in Psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib164","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, Double\u2010Blind, Placebo\u2010Controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib165","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"Tyk2\/Jak1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard-2023-223850_bib166","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-223850_bib167","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1367-5931(02)00357-5","article-title":"A strategy for the design of Multiplex inhibitors for kinase-mediated signalling in angiogenesis","volume":"6","author":"Adams","year":"2002","journal-title":"Curr Opin Chem Biol"},{"key":"10.1136\/ard-2023-223850_bib168","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the Jak1\/Jak3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond)"},{"key":"10.1136\/ard-2023-223850_bib169","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"10.1136\/ard-2023-223850_bib170","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/art.27536","article-title":"Selective functional inhibition of JAK\u20103 is sufficient for efficacy in Collagen\u2010Induced arthritis in mice","volume":"62","author":"Lin","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-223850_bib171","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/ar2365","article-title":"Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis","volume":"10","author":"Milici","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-223850_bib172","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of Glpg0634, a selective inhibitor of Jak1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J Immunol"},{"key":"10.1136\/ard-2023-223850_bib173","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by Filgotinib, Upadacitinib, tofacitinib and Baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib174","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bcp.12900","article-title":"Safety, pharmacokinetics and pharmacodynamics of Glpg0974, a potent and selective Ffa2 antagonist, in healthy male subjects","volume":"82","author":"Namour","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard-2023-223850_bib175","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1136\/ard-2023-223850_bib176","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of Jak1 and Jak2 is efficacious in rodent models of arthritis: Preclinical characterization of Incb028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol"},{"key":"10.1136\/ard-2023-223850_bib177","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the Jak1 selectivity of Upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib178","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jcph.1513","article-title":"Preferential inhibition of Jak1 relative to Jak3 by Upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib","volume":"60","author":"Mohamed","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1136\/ard-2023-223850_bib179","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1136\/ard-2023-223850_bib180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of Baricitinib, Upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human Leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-223850_bib181","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2023-223850_bib182","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164080","article-title":"Jak3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"key":"10.1136\/ard-2023-223850_bib183","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00281-019-00742-7","article-title":"T cell pathology in skin inflammation","volume":"41","author":"Sabat","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1136\/ard-2023-223850_bib184","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1136\/ard-2023-223850_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in Dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-223850_bib186","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric Alopecia Areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib187","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for Atopic dermatitis: a phase II a randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib188","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of Atopic dermatitis with Ruxolitinib cream (Jak1\/Jak2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2023-223850_bib189","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of Ruxolitinib cream for the treatment of Atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib190","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1021\/acs.jmedchem.0c00450","article-title":"Discovery of a Janus kinase inhibitor bearing a highly three-dimensional Spiro scaffold: JTE-052 (Delgocitinib) as a new dermatological agent to treat inflammatory skin disorders","volume":"63","author":"Noji","year":"2020","journal-title":"J Med Chem"},{"key":"10.1136\/ard-2023-223850_bib191","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/exd.13370","article-title":"A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents","volume":"27","author":"Tanimoto","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1136\/ard-2023-223850_bib192","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jdermsci.2016.09.007","article-title":"JAK inhibitor JTE-052 regulates contact hypersensitivity by Downmodulating T cell activation and differentiation","volume":"84","author":"Amano","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1136\/ard-2023-223850_bib193","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjd.16014","article-title":"Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe Atopic dermatitis: a phase II, Multicentre, randomized, vehicle-controlled clinical study","volume":"178","author":"Nakagawa","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib194","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe Atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib195","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/1346-8138.15173","article-title":"Long\u2010Term safety and efficacy of Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with Atopic dermatitis","volume":"47","author":"Nakagawa","year":"2020","journal-title":"J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib196","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","article-title":"Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo","volume":"64","author":"Tanimoto","year":"2015","journal-title":"Inflamm Res"},{"key":"10.1136\/ard-2023-223850_bib197","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical Delgocitinib in patients with chronic hand Eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study","volume":"182","author":"Worm","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib198","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjd.21037","article-title":"The Pan\u2010JAK inhibitor Delgocitinib in a cream formulation demonstrates dose response in chronic hand Eczema in a 16\u2010Week randomized phase IIb trial*","volume":"187","author":"Worm","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib199","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical Jak1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib200","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib201","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2B randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"key":"10.1136\/ard-2023-223850_bib202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2A efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib203","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of Vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223850_bib204","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of Ruxolitinib cream for Vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib205","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.2147\/DDDT.S354291","article-title":"Characterization of selective and potent Jak1 inhibitors intended for the inhaled treatment of asthma","volume":"16","author":"Nilsson","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1136\/ard-2023-223850_bib206","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-09241-6","article-title":"The Pan-JAK inhibitor Las194046 reduces neutrophil activation from severe asthma and COPD patients in vitro","volume":"12","author":"Milara","year":"2022","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2023-223850_bib207","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaci.2021.02.042","article-title":"Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial","volume":"148","author":"Braithwaite","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2023-223850_bib208","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Elevated levels of Interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19","volume":"146","author":"Herold","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2023-223850_bib209","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of Tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial","volume":"181","author":"Hermine","year":"2020","journal-title":"Jama Intern Med"},{"key":"10.1136\/ard-2023-223850_bib210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of Tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1136\/ard-2023-223850_bib211","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in patients hospitalized with COVID-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib212","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with COVID-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib213","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cell.2020.11.007","article-title":"Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-Cov-2-infected Rhesus macaques","volume":"184","author":"Hoang","year":"2021","journal-title":"Cell"},{"key":"10.1136\/ard-2023-223850_bib214","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; Multicentre study","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect"},{"key":"10.1136\/ard-2023-223850_bib215","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for hospitalized adults with COVID-19","volume":"384","author":"Kalil","year":"2020","journal-title":"New Engl J Medicine"},{"key":"10.1136\/ard-2023-223850_bib216","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(22)00088-1","article-title":"Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial","volume":"10","author":"Wolfe","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2023-223850_bib217","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of Baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2023-223850_bib218","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"22271623","author":"Horby","year":"2022","journal-title":"Medrxiv"},{"key":"10.1136\/ard-2023-223850_bib219","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of Baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or Extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2023-223850_bib220","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with COVID-19 pneumonia","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib221","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01311","article-title":"\u201c\u201csmall\u201d intestinal Immunopathology plays a \u201cbig\u201d role in lethal cytokine release syndrome, and its modulation by interferon-\u0393, IL-17A, and a Janus kinase inhibitor\u201d","volume":"11","author":"Kale","year":"2020","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2023-223850_bib222","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe Coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1136\/ard-2023-223850_bib223","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14787210.2021.1982695","article-title":"Janus kinase (JAK)-Inhibitors and Coronavirus disease 2019 (COVID-19) outcomes: a systematic review and meta-analysis","volume":"20","author":"Limen","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1136\/ard-2023-223850_bib224","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic Dmards with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician Registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib225","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib226","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjd.16798","article-title":"Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study","volume":"179","author":"Valenzuela","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2023-223850_bib227","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"10.1136\/ard-2023-223850_bib228","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib229","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with Baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib230","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","article-title":"Safety profile of Baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis","volume":"2","author":"Genovese","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2023-223850_bib231","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-223850_bib232","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib233","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib234","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib235","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of Upadacitinib over 15 000 patient-years across rheumatoid arthritis, Psoriatic arthritis, Ankylosing Spondylitis and Atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-223850_bib236","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying Antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-223850_bib237","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib238","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib239","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/annrheumdis-2020-218992","article-title":"Age-based (&Amp;Amp;Lt;65 vs \u226565 years) incidence of infections and serious infections with tofacitinib versus biological Dmards in rheumatoid arthritis clinical trials and the US Corrona RA Registry","volume":"80","author":"Winthrop","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib240","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","article-title":"Herpes Zoster in psoriasis patients treated with tofacitinib","volume":"77","author":"Winthrop","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard-2023-223850_bib241","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes Zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/ard-2023-223850_bib242","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40264-020-00904-9","article-title":"An integrated analysis of the safety of tofacitinib in Psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data","volume":"43","author":"Burmester","year":"2020","journal-title":"Drug Saf"},{"key":"10.1136\/ard-2023-223850_bib243","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1136\/ard-2023-223850_bib244","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/14397595.2020.1836789","article-title":"A pooled safety analysis of Peficitinib (Asp015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years","volume":"31","author":"Takeuchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib245","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","article-title":"Randomized phase 2B trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year: tofacitinib in kidney transplant patients","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1136\/ard-2023-223850_bib246","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1097\/TXD.0000000000000819","article-title":"Efficacy and safety of a tofacitinib-based immunosuppressive regimen after kidney transplantation: results from a long-term extension trial","volume":"4","author":"Busque","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1136\/ard-2023-223850_bib247","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"Jak1\/2 inhibition with Baricitinib in the treatment of Autoinflammatory Interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2023-223850_bib248","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar4673","article-title":"Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials","volume":"16","author":"Isaacs","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-223850_bib249","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13075-015-0612-7","article-title":"Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial","volume":"17","author":"Kremer","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-223850_bib250","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/annrheumdis-2013-203380","article-title":"Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study","volume":"73","author":"Chung","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib251","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/annrheumdis-2012-201669","article-title":"The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study","volume":"72","author":"Choi","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib252","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib253","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and Psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib254","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","article-title":"The Ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in Myeloproliferative Neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J Transl Med"},{"key":"10.1136\/ard-2023-223850_bib255","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The impact of Ruxolitinib on thrombosis in patients with Polycythemia Vera and myelofibrosis","volume":"27","author":"Samuelson","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1136\/ard-2023-223850_bib256","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with Baricitinib compared to Tnfi: A multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2023-223850_bib257","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of Baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib258","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","article-title":"Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies","volume":"56","author":"Schulze-Koops","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-223850_bib259","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001370","article-title":"Changes in selected haematological parameters associated with Jak1\/Jak2 inhibition observed in patients with rheumatoid arthritis treated with Baricitinib","volume":"6","author":"Kay","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-223850_bib260","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological Disease\u2010Modifying Antirheumatic drugs: 5\u2010Year results from a United States\u2013based rheumatoid arthritis Registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib261","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib262","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of Interleukin-6 receptor blockade on Surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib263","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of Tocilizumab versus Etanercept in rheumatoid arthritis: A randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib264","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase Iiiand Long\u2010Term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223850_bib265","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2016.03.004","article-title":"Effects of tofacitinib and other Dmards on lipid profiles in rheumatoid arthritis: implications for the Rheumatologist","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-223850_bib266","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"supplement_1","key":"10.1136\/ard-2023-223850_bib267","doi-asserted-by":"crossref","first-page":"S023","DOI":"10.1093\/ecco-jcc\/jjx180.032","article-title":"Op033 the effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme","volume":"12","author":"Sands","year":"2018","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1136\/ard-2023-223850_bib268","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-223850_bib269","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib270","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-223850_bib271","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib272","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223850_bib273","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of new Biologics (Vedolizumab and Ustekinumab) and small molecules (tofacitinib) during pregnancy: A review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs"},{"key":"10.1136\/ard-2023-223850_bib274","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"10.1136\/ard-2023-223850_bib275","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/ard-2023-223850_bib276","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s12325-022-02168-4","article-title":"MANTA and MANTA-ray: rationale and design of trials evaluating effects of Filgotinib on semen parameters in patients with inflammatory diseases","volume":"39","author":"Hellstrom","year":"2022","journal-title":"Adv Ther"},{"key":"10.1136\/ard-2023-223850_bib277","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1073\/pnas.87.18.6934","article-title":"Structural design and molecular evolution of a cytokine receptor Superfamily","volume":"87","author":"Bazan","year":"1990","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672400339X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672400339X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-223850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:03:32Z","timestamp":1786201412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672400339X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":277,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S000349672400339X"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-223850","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-223850","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}